Caremo Selected as 2024 Nanjing Postdoctoral Innovation Practice Base!

Recently, the Nanjing Municipal Human Resources And Social Security Bureau announced the 2024 list of Nanjing Postdoctoral Innovation Practice Bases. Nanjing Caremo Biopharmaceutical Co., Ltd. (hereinafter referred to as "Caremo") was successfully recognized for its robust scientific innovation capabilities and strong talent pool.

The Nanjing Postdoctoral Innovation Practice Base initiative is a key platform for the city to advance its innovation-driven development strategy and attract top-tier talent. It aims to deepen the integration of industry, academia, and research, accelerate the commercialization of scientific achievements, and foster high-level talent cultivation. To qualify, enterprises must demonstrate leading industry status, strong economic and R&D capabilities, and possess well-established research institutions with highly qualified teams.

Caremo has consistently prioritized young talent as a vital resource for corporate growth, emphasizing both recruitment and development. This selection underscores Caremo’s strengths in pharmaceutical R&D, industry-academia-research collaboration, and talent aggregation. It not only acknowledges the company’s current achievements but also reflects expectations for its future innovation trajectory.

Looking ahead, Caremo will focus on building a world-class research environment to attract postdoctoral innovators. The company will provide expanded platforms for high-level talent, encourage original research, and expedite the transformation of scientific outcomes into real-world applications. Through these efforts, Caremo aims to bolster Nanjing’s vision of becoming a global innovation hub and contribute to the city’s accelerated development as a leader in scientific advancement.